Published in J Med Genet on September 01, 2004
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43
Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol (2012) 2.40
Colorectal cancer molecular biology moves into clinical practice. Gut (2010) 2.32
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn (2006) 2.11
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer (2007) 1.77
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn (2009) 1.72
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer (2006) 1.68
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology (2014) 1.57
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol (2013) 1.41
Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat (2008) 1.35
BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer (2010) 1.23
EGFR Signaling in Colorectal Carcinoma. Patholog Res Int (2011) 1.20
Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol (2014) 1.16
The CpG island methylator phenotype in colorectal cancer. J Mol Diagn (2007) 1.15
B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14
Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov (2013) 1.10
DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol (2010) 1.07
Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer (2013) 1.06
Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. Clin Cancer Res (2010) 1.05
Pathology of the hereditary colorectal carcinoma. Fam Cancer (2007) 1.04
HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer (2007) 1.04
De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer (2011) 1.02
MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions. Fam Cancer (2010) 1.00
Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn (2010) 0.98
Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res (2013) 0.98
Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol (2012) 0.97
A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med (2009) 0.96
Aspirin and colorectal cancer: back to the future. Clin Cancer Res (2013) 0.95
MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet (2012) 0.94
Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer (2009) 0.93
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol (2012) 0.93
Multivariate analysis of MLH1 c.1664T>C (p.Leu555Pro) mismatch repair gene variant demonstrates its pathogenicity. Fam Cancer (2013) 0.93
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92
Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int (2015) 0.92
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res (2015) 0.92
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. PLoS One (2013) 0.91
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol (2010) 0.91
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol (2014) 0.90
EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients. J Mol Diagn (2010) 0.90
Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome. Fam Cancer (2012) 0.90
Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers (Basel) (2011) 0.89
Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. J Clin Oncol (2013) 0.88
Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. Br J Cancer (2010) 0.88
Utility of p16 immunohistochemistry for the identification of Lynch syndrome. Clin Cancer Res (2009) 0.87
Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review. Fam Cancer (2014) 0.87
Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol (2013) 0.86
Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother (2016) 0.86
Molecular basis for subdividing hereditary colon cancer? Gut (2005) 0.85
An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res (2010) 0.85
The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. Eur J Hum Genet (2013) 0.85
Genomic instability and carcinogenesis: an update. Curr Genomics (2008) 0.84
Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol (2013) 0.83
Tumor histology helps to identify Lynch syndrome among colorectal cancer patients. Fam Cancer (2008) 0.81
A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer (2014) 0.81
Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des (2014) 0.80
Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol (2014) 0.80
Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives. PLoS Curr (2013) 0.80
Microsatellite instability in gallbladder carcinoma. Virchows Arch (2015) 0.80
hMLH1 promoter methylation and BRAF mutations in high-frequency microsatellite instability colorectal cancers not fulfilling the revised Bethesda guidelines. Ann Surg Treat Res (2014) 0.79
A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours. Fam Cancer (2012) 0.79
High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer. J Mol Histol (2012) 0.79
Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1. Urology (2013) 0.79
Ingredients for success: a familial cancer clinic in an oncology practice setting. J Oncol Pract (2011) 0.79
The role of epigenetics in Lynch syndrome. Fam Cancer (2013) 0.79
Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol (2017) 0.78
Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol (2011) 0.78
Pancreatic cancer and a novel MSH2 germline alteration. Pancreas (2011) 0.78
From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol (2016) 0.78
Lynch syndrome: clinical, pathological, and genetic insights. Langenbecks Arch Surg (2012) 0.78
MLH1 promotor hypermethylation does not rule out a diagnosis of Lynch syndrome: a case report. Fam Cancer (2015) 0.77
The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking β-Catenin/TCF Regulated Transcription. Gastroenterol Res Pract (2016) 0.77
Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. Int J Cancer (2016) 0.77
KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer? Gastroenterol Res Pract (2015) 0.76
Unifying cancer genetics. Genet Med (2011) 0.76
Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. Fam Cancer (2014) 0.76
The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci (2014) 0.76
Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas. Virchows Arch (2016) 0.76
Clinical implications of BRAF mutation test in colorectal cancer. Gastroenterol Hepatol Bed Bench (2013) 0.76
A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors. Res Pharm Sci (2016) 0.75
Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Med (2016) 0.75
Novel Mutations in MLH1 and MSH2 Genes in Mexican Patients with Lynch Syndrome. Gastroenterol Res Pract (2016) 0.75
Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). J Gastrointest Oncol (2017) 0.75
Systematic study on genetic and epimutational profile of a cohort of Amsterdam criteria-defined Lynch Syndrome in Singapore. PLoS One (2014) 0.75
BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer. Gastroenterol Rep (Oxf) (2013) 0.75
The mutational spectrum of Lynch syndrome in cyprus. PLoS One (2014) 0.75
Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers. J Gastrointest Cancer (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet (1999) 4.16
Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol (2000) 3.98
Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A (1998) 3.90
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res (2003) 3.39
Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet (1997) 3.34
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet (2001) 2.68
Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst (1995) 2.62
Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res (1993) 2.48
Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med (1995) 2.40
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res (2004) 2.37
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res (2003) 1.92
Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene (2003) 1.82
Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer (2002) 1.65
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med (2001) 1.50
Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer (2002) 1.23
Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer (2004) 1.18
Various mutation screening techniques in the DNA mismatch repair genes hMSH2 and hMLH1. Genet Test (1999) 1.14
Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet (2004) 1.03
A greedy algorithm for aligning DNA sequences. J Comput Biol (2000) 47.89
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A (2003) 14.01
Comparative analyses of multi-species sequences from targeted genomic regions. Nature (2003) 13.31
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35
Interstitial Myocarditis Following the Clinical and Experimental Use of Sulfonamide Drugs. Am J Pathol (1942) 10.27
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
Boron nitride substrates for high-quality graphene electronics. Nat Nanotechnol (2010) 9.72
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Linkage group I: the simultaneous estimation of recombination and interference. Birth Defects Orig Artic Ser (1976) 8.63
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (1994) 8.04
A perpendicular-anisotropy CoFeB-MgO magnetic tunnel junction. Nat Mater (2010) 7.78
Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature (1992) 7.66
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J (1998) 7.59
Control of memory formation through regulated expression of a CaMKII transgene. Science (1996) 7.56
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (1997) 7.31
Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science (1998) 7.08
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (1999) 6.73
Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization. J Immunol (1980) 6.69
Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke (2001) 6.61
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
New Ballard Score, expanded to include extremely premature infants. J Pediatr (1991) 5.82
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med (1998) 5.65
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer (2007) 5.38
The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell (1996) 5.20
arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature (2000) 5.13
Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol (1994) 5.13
Socioeconomic status and psychiatric disorders: the causation-selection issue. Science (1992) 4.95
Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res (1993) 4.93
A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim (1999) 4.93
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1972) 4.64
Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke (2001) 4.64
Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology (2002) 4.45
A dust-obscured massive maximum-starburst galaxy at a redshift of 6.34. Nature (2013) 4.43
Portomesenteric vein gas: pathologic mechanisms, CT findings, and prognosis. Radiographics (2000) 4.43
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res (1998) 4.39
Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet (1997) 4.27
Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet (2007) 4.13
Genetic mapping of a locus predisposing to human colorectal cancer. Science (1993) 4.12
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10
Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A (1992) 4.08
Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med (2011) 4.04
Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet (1995) 4.01
Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol (2000) 3.98
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84
Comparative sequence analysis of a gene-rich cluster at human chromosome 12p13 and its syntenic region in mouse chromosome 6. Genome Res (1998) 3.80
Inherited microdeletions in the Angelman and Prader-Willi syndromes define an imprinting centre on human chromosome 15. Nat Genet (1995) 3.79
Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc Natl Acad Sci U S A (1998) 3.72
Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science (1995) 3.66
The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci (2006) 3.62
Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry (2009) 3.56
National character does not reflect mean personality trait levels in 49 cultures. Science (2005) 3.56
Is routine indwelling catheterisation of the bladder for caesarean section necessary? A systematic review. BJOG (2010) 3.54
Ballistic 2-d imaging through scattering walls using an ultrafast optical kerr gate. Science (1991) 3.53
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci U S A (1996) 3.53
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
The action of gamma-aminobutyric acid on cortical neurones. Exp Brain Res (1967) 3.45
Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem (1998) 3.39
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A (2000) 3.37
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet (2000) 3.33
Proposals of Sphingomonas paucimobilis gen. nov. and comb. nov., Sphingomonas parapaucimobilis sp. nov., Sphingomonas yanoikuyae sp. nov., Sphingomonas adhaesiva sp. nov., Sphingomonas capsulata comb. nov., and two genospecies of the genus Sphingomonas. Microbiol Immunol (1990) 3.33
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Structure of chromosomal duplicons and their role in mediating human genomic disorders. Genome Res (2000) 3.30
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med (2001) 3.27
Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res (1994) 3.25
Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science (1998) 3.22
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab (2003) 3.19
DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol (1999) 3.17
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet (1999) 3.14
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology (2000) 3.01
Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr (1999) 3.01
Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS (1996) 2.95
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet (2004) 2.95
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell (2000) 2.94
Contralateral thalamic perfusion in patients with reflex sympathetic dystrophy syndrome. Lancet (1999) 2.93
Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med (1999) 2.92
Comparative analysis of the gene-dense ACHE/TFR2 region on human chromosome 7q22 with the orthologous region on mouse chromosome 5. Nucleic Acids Res (2001) 2.89
Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology (2001) 2.89
Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res (1996) 2.89
Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer (1995) 2.85
Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci (2001) 2.84
The reeler gene-associated antigen on Cajal-Retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron (1995) 2.82
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81